介入心脏病学领域是以证据和数据为基础的，在过去几年中该领域发展迅猛。作为世界上最大的介入会议之一， TCT逐步成为首要的呈现心血管领域内最新临床试验最新数据的会议。在 2009年，除了在各种科学研讨会和同步会议上进行摘要和最新数据的报告外， TCT主会场对 18个最新临床试验结果进行了公布。

    最新临床试验从最新的、由研究者发起的研究，如评估主动脉内气囊反搏在高危 PCI中效用的试验（ BCIS-1）和评估超声引导经股动脉进行操作的研究（ FAUST），到大型国际临床试验观察经皮冠脉介入治疗时抗血小板治疗的应用（ CURRENT-PCI OASIS 7和PLATO Invasive）。其他的新型有创技术的报告，例如，通过肾去交感神经支配治疗系统性高血压的方法（SYMPLICITY I），以及首个易损斑块自然发展过程前瞻性研究（ PROSPECT），能够让听众看到介入心脏病学领域未来发展情况。

    为了将最新数据纳入合理的临床视点，在主会场每个最新临床试验报告之后，会有特定讨论者进行评论，思想领袖主持进行专题讨论。新闻发布会上发布专家小组讨论问答的内容，也促进了这些结果向公众的传播。总的来说，多年来对最新临床试验版块反馈的资料清晰地表明，介入心脏病学领域在不断壮大， TCT有能力在介入领域成为突破性临床数据公布的最受欢迎会议之一。

Premier Venues for Presenting New Progress

Ajay J. Kirtane

    The field of Interventional Cardiology is often recognized as one of the most evidence-based and data-driven, and there has truly been an explosion of new data within the field over the past several years.  As one of the largest Interventional meetings in the world, TCT has evolved to become one of the premier venues for the presentation of novel data and late-breaking clinical trials within the field.  In 2009, in addition to the presentation of abstracts and new data at the various scientific symposia and concurrent sessions, a total of 18 late-breaking clinical trials were presented in the TCT main arena.

    These late-breaking trials ranged from novel investigator-initiated studies such as those assessing the utility of intra-aortic balloon pump counterpulsation in high-risk PCI (BCIS-1) and a study evaluating the use of routine femoral artery ultrasongraphy prior to arterial access (FAUST) to large international trials examining the usage of novel antiplatelet therapies during percutaneous coronary intervention (CURRENT-PCI OASIS 7 and PLATO Invasive).  Other presentations of new invasive techniques, for example, a way to treat systemic hypertension through sympathetic renal denervation (SYMPLICITY I), as well as one of the first prospectively conducted natural history studies of vulnerable plaque (PROSPECT) allowed the audience to gain a glimpse of the potential future of the field of Interventional Cardiology.

    In order to place the novel data in the appropriate clinical perspective, following the presentation of each late-breaking trial in the main arena, a designated discussant provided commentary, and a moderated panel discussion with thought leaders specifically selected to match each session ensued.  Separate press conferences involving question and answer sessions with expert panel discussants also facilitated dissemination of these results to the general public.

    Overall, the feedback that has been garnered over the years from the late-breaking trials sessions clearly indicates that as the field of Interventional Cardiology continues to expand, so has the ability of TCT to stand as one of the most sought-after venues for the presentation of groundbreaking clinical data in the Interventional space.